Developer docs
API playgroundTry for free, no card

Search company profiles

V-Wave

Full company profile

uuid0000h3n

Namestring
V-Wave
Legal namestring
V-Wave Ltd.
Company typeenum
Private
Founded yearint
2009
Descriptiontext

V-Wave Ltd. is an Israel-based medical device company founded in 2009 (originally headquartered in Caesarea with a U.S. office in Agoura Hills, California) that developed the Ventura Interatrial Shunt, a novel hourglass-shaped, percutaneously implanted device designed to reduce elevated left atrial pressure by offloading blood volume from the left atrium to the right atrium in patients with heart failure with reduced ejection fraction (HFrEF). The shunt is encapsulated in expanded polytetrafluoroethylene (ePTFE) to limit tissue ingrowth, contains no battery or moving parts, and is delivered via a minimally invasive right-sided femoral catheterization procedure averaging approximately 80 minutes total (with roughly 14 minutes of fluoroscopy and no radiocontrast required). The device is MR Conditional at 1.5T and 3T, and is supported by at least three U.S. patents (10,251,740; 10,076,403; 11,850,138).

The company's clinical evidence base is anchored by the RELIEVE-HF pivotal randomized controlled trial, which enrolled 508 patients (plus 97 roll-in) across 94 hospitals in 11 countries and demonstrated a 48% reduction in heart failure hospitalizations and 45% reduction in combined cardiovascular events over 24 months in the HFrEF subgroup, with 100% implant success and 0% device-related major adverse events. V-Wave received FDA Breakthrough Device Designation (2019, both for heart failure and PAH) and CE Mark approval (March 2020), and is also pursuing a Pulmonary Arterial Hypertension (PAH) indication under an FDA IDE Early Feasibility Study.

V-Wave operated as a privately held, venture-backed pre-revenue company funded through a $28M Series B (2016), $70M Series C (2018), and up to $98M Series C extension (2020-2021), with a strategic syndicate that included Johnson & Johnson Innovation – JJDC and Edwards Lifesciences. On October 9, 2024, Johnson & Johnson completed the acquisition of V-Wave for $600 million upfront plus up to $1.1 billion in regulatory and commercial milestones (total deal value up to $1.7 billion), and V-Wave now operates as part of Johnson & Johnson MedTech, with future commercialization intended to leverage J&J's cardiovascular sales infrastructure targeting approximately 800,000 annual U.S. HFrEF patients. Notably, in December 2025 an FDA advisory panel rejected the Ventura Shunt over effectiveness concerns and the need for additional clinical data, creating material uncertainty for the U.S. regulatory and commercial pathway.

Short descriptiontext

V-Wave develops the Ventura Interatrial Shunt, a percutaneous implant that lowers left atrial pressure in NYHA Class III HFrEF patients. Acquired by Johnson & Johnson MedTech in October 2024 (up to $1.7B); remains an investigational device.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCaesarea, Israel
HQ citystring
Caesarea
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
interatrial shunt device, heart failure therapy, cardiovascular medical devices, percutaneous implants, structural heart interventions
Industry2 codes
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAB
Interventional Cardiology (PCI/Structural Heart)
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiovascular Medical Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales (Planned)
TypeHardware Sales
Description

V-Wave's Ventura Interatrial Shunt is an investigational device not yet commercially available. Upon regulatory approval, the product will be sold through Johnson & Johnson MedTech's cardiovascular sales infrastructure. Revenue will be generated through hospital/healthcare system purchases of the implantable device and associated procedural costs.

prod.vwavemedical.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Ventura Interatrial Shunt
Description

The V-Wave Ventura Interatrial Shunt is a novel, hourglass-shaped implantable device designed to reduce increases in left atrial pressure by offloading volume from the left atrium to the right atrium for treating heart failure.

vwavemedical.com
+1 more record
Core offering1 text field

V-Wave develops and intends to commercialize the Ventura Interatrial Shunt, a novel, hourglass-shaped, percutaneously implanted device with ePTFE biocompatible encapsulation designed to reduce elevated left atrial pressure by offloading volume from the left atrium to the right atrium in patients with NYHA Class III heart failure with reduced ejection fraction (HFrEF). The device is delivered via a minimally invasive right-sided femoral catheterization procedure and has FDA Breakthrough Device Designation and CE Mark approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 48% reduction in heart failure hospitalizations over 24 months in HFrEF patients (LVEF ≤40%)
+4 more records
Product overview1 text field

V-Wave is a medical device company with a single core product—the V-Wave Ventura Interatrial Shunt. This investigational device is a novel, hourglass-shaped shunt that creates a pathway between the left and right atrium to reduce elevated left atrial pressure in heart failure patients. The company was established in Israel in 2009 and was acquired by Johnson & Johnson in October 2024, becoming part of Johnson & Johnson MedTech. The Ventura Interatrial Shunt has received FDA Breakthrough Device Designation (2019) and CE Mark approval in the EU (2020), but remains an investigational device in the United States. The pivotal RELIEVE-HF trial demonstrated significant benefits for HFrEF patients, including 45% fewer cardiovascular events and 48% fewer heart failure hospitalizations over 24 months.

Product and service1 record
1V-Wave Ventura Interatrial Shunt
CategoryCardiovascular implantable medical device
Description

A novel, hourglass-shaped, percutaneously implanted interatrial shunt with ePTFE biocompatible encapsulation designed to reduce elevated left atrial pressure by offloading volume from the left atrium to the right atrium. It is intended for NYHA Class III heart failure patients with reduced ejection fraction (HFrEF, LVEF ≤40%) who remain symptomatic despite maximally tolerated guideline-directed medical therapy. The device is delivered via a minimally invasive right-sided femoral catheterization procedure.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1RELIEVE-HF Clinical Trial Network (94 hospitals, 11 countries)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-06
Description

V-Wave conducted the RELIEVE-HF pivotal trial at 94 hospitals across 11 countries including the U.S., EU, Israel, Australia, and New Zealand. Key principal investigators include Dr. Gregg Stone (Columbia University/Mount Sinai), Dr. Joann Lindenfeld (Vanderbilt), Dr. Stefan Anker (Charité Berlin), and Dr. Josep Rodés-Cabau (Laval University). First patients were implanted at Ohio State University Wexner Medical Center.

prod.vwavemedical.com
2EU Notified Body (CE Mark)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-03-05
Description

The Ventura Interatrial Shunt System received CE Mark approval in March 2020, certifying conformance to European Medical Device Directive standards and enabling marketing in the European Union.

prod.vwavemedical.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-09-12
Description

The FDA granted V-Wave's interatrial shunt Breakthrough Device Designation in August 2019 for heart failure, and a second designation in September 2019 for pulmonary arterial hypertension. The Breakthrough Devices Program facilitates interactive communication with the FDA and prioritized review of submissions and marketing applications.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Corvia Medical develops the InterAtrial Shunt Device (IASD), the most direct competitor to V-Wave's Ventura. Both target NYHA Class III HFrEF patients via percutaneous interatrial shunting to reduce left atrial pressure, making Corvia the closest head-to-head competitor in clinical and commercial positioning.

TypeBroad incumbent
Description

Edwards Lifesciences is a global leader in structural heart therapies (TAVR/surgical valves) and was an early V-Wave investor via its Series B. Its structural heart sales channel and heart failure focus make it a broad incumbent competitor and a potential strategic acquirer in the heart failure device space.

3Abbott
TypeBroad incumbent
Description

Abbott's cardiovascular portfolio (CardioMEMS HF System, MitraClip, structural heart) competes in the same heart failure and structural heart cath lab channels where Ventura will be commercialized. CardioMEMS in particular addresses a similar NYHA Class III HF population via pulmonary pressure monitoring.

TypeBroad incumbent
Description

Medtronic is a major cardiovascular medical device incumbent with heart failure, structural heart, and interventional cardiology franchises. Its scale and cath lab relationships make it a broad incumbent competitor for hospital purchasing decisions in the HFrEF device category.

TypeBroad incumbent
Description

Boston Scientific's interventional cardiology and structural heart portfolio (Watchman, ACURATE neo) competes for the same hospital cath lab resources and physician mindshare as V-Wave's Ventura Shunt, particularly in heart failure patients with comorbidities.

TypeEmerging player
Description

Ancora Heart is developing the AccuCinch System, a percutaneous ventricular repair device for HFrEF. It targets a similar NYHA Class III HFrEF patient population via a different mechanism (ventricular reshaping rather than atrial shunting), making it a partial-overlap emerging competitor.

TypeEmerging player
Description

BioVentrix develops the Revivent TC system for less invasive ventricular restoration in ischemic heart failure patients. Like V-Wave, it targets advanced HFrEF patients and is an emerging structural heart player with overlapping cath lab/heart failure treatment positioning.

TypeEmerging player
Description

Cardiac Dimensions markets the Carillon Mitral Contour System for functional mitral regurgitation in heart failure patients. It addresses an overlapping HF patient population and uses a similar percutaneous catheter-based delivery approach in the structural heart cath lab setting.

TypeEmerging player
Description

Axon Therapies is developing splanchnic nerve ablation (SNA) for heart failure, targeting a similar HFrEF/NYHA Class III population via a catheter-based procedure. It represents an emerging alternative interventional approach that could compete with Ventura for the same patient and physician base.

TypeOthers
Description

Shockwave Medical (acquired by J&J in 2024 for $13B alongside V-Wave) is a sibling J&J MedTech cardiovascular asset. While focused on intravascular lithotripsy rather than heart failure, it shares the same J&J cardiovascular sales channel and serves as a useful comp for J&J's cardiovascular go-to-market playbook that V-Wave will leverage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

V-Wave

Cardiovascular Medical Devicesvwavemedical.com

V-Wave develops the Ventura Interatrial Shunt, a percutaneous implant that lowers left atrial pressure in NYHA Class III HFrEF patients. Acquired by Johnson & Johnson MedTech in October 2024 (up to $1.7B); remains an investigational device.

What V-Wave does

V-Wave Ltd. is an Israel-based medical device company founded in 2009 (originally headquartered in Caesarea with a U.S. office in Agoura Hills, California) that developed the Ventura Interatrial Shunt, a novel hourglass-shaped, percutaneously implanted device designed to reduce elevated left atrial pressure by offloading blood volume from the left atrium to the right atrium in patients with heart failure with reduced ejection fraction (HFrEF). The shunt is encapsulated in expanded polytetrafluoroethylene (ePTFE) to limit tissue ingrowth, contains no battery or moving parts, and is delivered via a minimally invasive right-sided femoral catheterization procedure averaging approximately 80 minutes total (with roughly 14 minutes of fluoroscopy and no radiocontrast required). The device is MR Conditional at 1.5T and 3T, and is supported by at least three U.S. patents (10,251,740; 10,076,403; 11,850,138).

The company's clinical evidence base is anchored by the RELIEVE-HF pivotal randomized controlled trial, which enrolled 508 patients (plus 97 roll-in) across 94 hospitals in 11 countries and demonstrated a 48% reduction in heart failure hospitalizations and 45% reduction in combined cardiovascular events over 24 months in the HFrEF subgroup, with 100% implant success and 0% device-related major adverse events. V-Wave received FDA Breakthrough Device Designation (2019, both for heart failure and PAH) and CE Mark approval (March 2020), and is also pursuing a Pulmonary Arterial Hypertension (PAH) indication under an FDA IDE Early Feasibility Study.

V-Wave operated as a privately held, venture-backed pre-revenue company funded through a $28M Series B (2016), $70M Series C (2018), and up to $98M Series C extension (2020-2021), with a strategic syndicate that included Johnson & Johnson Innovation – JJDC and Edwards Lifesciences. On October 9, 2024, Johnson & Johnson completed the acquisition of V-Wave for $600 million upfront plus up to $1.1 billion in regulatory and commercial milestones (total deal value up to $1.7 billion), and V-Wave now operates as part of Johnson & Johnson MedTech, with future commercialization intended to leverage J&J's cardiovascular sales infrastructure targeting approximately 800,000 annual U.S. HFrEF patients. Notably, in December 2025 an FDA advisory panel rejected the Ventura Shunt over effectiveness concerns and the need for additional clinical data, creating material uncertainty for the U.S. regulatory and commercial pathway.

V-Wave firmographics

Firmographics
Name
V-Wave
Legal name
V-Wave Ltd.
Website
https://vwavemedical.com
Company type
Private
Founded year
2009
Operating status
Acquired
Headcount range
11–50 employees
Short description
V-Wave develops the Ventura Interatrial Shunt, a percutaneous implant that lowers left atrial pressure in NYHA Class III HFrEF patients. Acquired by Johnson & Johnson MedTech in October 2024 (up to $1.7B); remains an investigational device.
Ownership category
akta.pro rank

V-Wave industry classification

Industry
Product category
Cardiovascular Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAB
Interventional Cardiology (PCI/Structural Heart)

Keywords

  • Interatrial shunt device
  • Heart failure therapy
  • Cardiovascular medical devices
  • Percutaneous implants
  • Structural heart interventions

Where V-Wave is headquartered

Location

Headquarters

HQ city
Caesarea
HQ country
Israel
HQ region
Middle East

Offices3 records

Markets served

V-Wave business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Medical Device Sales (Planned): V-Wave's Ventura Interatrial Shunt is an investigational device not yet commercially available. Upon regulatory approval, the product will be sold through Johnson & Johnson MedTech's cardiovascular sales infrastructure. Revenue will be generated through hospital/healthcare system purchases of the implantable device and associated procedural costs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

V-Wave product offering

Product offering

Core offering

V-Wave develops and intends to commercialize the Ventura Interatrial Shunt, a novel, hourglass-shaped, percutaneously implanted device with ePTFE biocompatible encapsulation designed to reduce elevated left atrial pressure by offloading volume from the left atrium to the right atrium in patients with NYHA Class III heart failure with reduced ejection fraction (HFrEF). The device is delivered via a minimally invasive right-sided femoral catheterization procedure and has FDA Breakthrough Device Designation and CE Mark approval.

Product overview

V-Wave is a medical device company with a single core product—the V-Wave Ventura Interatrial Shunt. This investigational device is a novel, hourglass-shaped shunt that creates a pathway between the left and right atrium to reduce elevated left atrial pressure in heart failure patients. The company was established in Israel in 2009 and was acquired by Johnson & Johnson in October 2024, becoming part of Johnson & Johnson MedTech. The Ventura Interatrial Shunt has received FDA Breakthrough Device Designation (2019) and CE Mark approval in the EU (2020), but remains an investigational device in the United States. The pivotal RELIEVE-HF trial demonstrated significant benefits for HFrEF patients, including 45% fewer cardiovascular events and 48% fewer heart failure hospitalizations over 24 months.

Differentiator

Problem solved

Functional benefit

Brands

  • Ventura Interatrial Shunt: The V-Wave Ventura Interatrial Shunt is a novel, hourglass-shaped implantable device designed to reduce increases in left atrial pressure by offloading volume from the left atrium to the right atrium for treating heart failure.
  • Magical Shunt

Products and services

  • V-Wave Ventura Interatrial Shunt A novel, hourglass-shaped, percutaneously implanted interatrial shunt with ePTFE biocompatible encapsulation designed to reduce elevated left atrial pressure by offloading volume from the left atrium to the right atrium. It is intended for NYHA Class III heart failure patients with reduced ejection fraction (HFrEF, LVEF ≤40%) who remain symptomatic despite maximally tolerated guideline-directed medical therapy. The device is delivered via a minimally invasive right-sided femoral catheterization procedure.

Quantifiable outcome

  • 48% reduction in heart failure hospitalizations over 24 months in HFrEF patients (LVEF ≤40%)
  • +4 more outcomes

Companies that use V-Wave

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

V-Wave technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

V-Wave partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • RELIEVE-HF Clinical Trial Network (94 hospitals, 11 countries)coreStrategic or Co-development Partner · 6 April 2024V-Wave conducted the RELIEVE-HF pivotal trial at 94 hospitals across 11 countries including the U.S., EU, Israel, Australia, and New Zealand. Key principal investigators include Dr. Gregg Stone (Columbia University/Mount Sinai), Dr. Joann Lindenfeld (Vanderbilt), Dr. Stefan Anker (Charité Berlin), and Dr. Josep Rodés-Cabau (Laval University). First patients were implanted at Ohio State University Wexner Medical Center.
  • EU Notified Body (CE Mark)coreStrategic or Co-development Partner · 5 March 2020The Ventura Interatrial Shunt System received CE Mark approval in March 2020, certifying conformance to European Medical Device Directive standards and enabling marketing in the European Union.
  • FDA (Breakthrough Devices Program)coreStrategic or Co-development Partner · 12 September 2019The FDA granted V-Wave's interatrial shunt Breakthrough Device Designation in August 2019 for heart failure, and a second designation in September 2019 for pulmonary arterial hypertension. The Breakthrough Devices Program facilitates interactive communication with the FDA and prioritized review of submissions and marketing applications.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

V-Wave competitors and assessment

Company assessment

Direct peers

  • Corvia Medical: Corvia Medical develops the InterAtrial Shunt Device (IASD), the most direct competitor to V-Wave's Ventura. Both target NYHA Class III HFrEF patients via percutaneous interatrial shunting to reduce left atrial pressure, making Corvia the closest head-to-head competitor in clinical and commercial positioning.

Broad incumbents

  • Edwards Lifesciences: Edwards Lifesciences is a global leader in structural heart therapies (TAVR/surgical valves) and was an early V-Wave investor via its Series B. Its structural heart sales channel and heart failure focus make it a broad incumbent competitor and a potential strategic acquirer in the heart failure device space.
  • Abbott: Abbott's cardiovascular portfolio (CardioMEMS HF System, MitraClip, structural heart) competes in the same heart failure and structural heart cath lab channels where Ventura will be commercialized. CardioMEMS in particular addresses a similar NYHA Class III HF population via pulmonary pressure monitoring.
  • Medtronic: Medtronic is a major cardiovascular medical device incumbent with heart failure, structural heart, and interventional cardiology franchises. Its scale and cath lab relationships make it a broad incumbent competitor for hospital purchasing decisions in the HFrEF device category.
  • Boston Scientific: Boston Scientific's interventional cardiology and structural heart portfolio (Watchman, ACURATE neo) competes for the same hospital cath lab resources and physician mindshare as V-Wave's Ventura Shunt, particularly in heart failure patients with comorbidities.

Emerging players

  • Ancora Heart: Ancora Heart is developing the AccuCinch System, a percutaneous ventricular repair device for HFrEF. It targets a similar NYHA Class III HFrEF patient population via a different mechanism (ventricular reshaping rather than atrial shunting), making it a partial-overlap emerging competitor.
  • BioVentrix: BioVentrix develops the Revivent TC system for less invasive ventricular restoration in ischemic heart failure patients. Like V-Wave, it targets advanced HFrEF patients and is an emerging structural heart player with overlapping cath lab/heart failure treatment positioning.
  • Cardiac Dimensions: Cardiac Dimensions markets the Carillon Mitral Contour System for functional mitral regurgitation in heart failure patients. It addresses an overlapping HF patient population and uses a similar percutaneous catheter-based delivery approach in the structural heart cath lab setting.
  • Axon Therapies: Axon Therapies is developing splanchnic nerve ablation (SNA) for heart failure, targeting a similar HFrEF/NYHA Class III population via a catheter-based procedure. It represents an emerging alternative interventional approach that could compete with Ventura for the same patient and physician base.

Others

  • Shockwave Medical: Shockwave Medical (acquired by J&J in 2024 for $13B alongside V-Wave) is a sibling J&J MedTech cardiovascular asset. While focused on intravascular lithotripsy rather than heart failure, it shares the same J&J cardiovascular sales channel and serves as a useful comp for J&J's cardiovascular go-to-market playbook that V-Wave will leverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

V-Wave social profiles

Digital presence

V-Wave compliance and trust

Trust signal

Compliance3 records

V-Wave financial estimates

Financial estimate

Revenue estimate

Valuation estimate

V-Wave leadership team

Management profile

Number of profiles

Profiles15 records

V-Wave funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

V-Wave M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about V-Wave

What does V-Wave do?

V-Wave develops and intends to commercialize the Ventura Interatrial Shunt, a novel, hourglass-shaped, percutaneously implanted device with ePTFE biocompatible encapsulation designed to reduce elevated left atrial pressure by offloading volume from the left atrium to the right atrium in patients with NYHA Class III heart failure with reduced ejection fraction (HFrEF). The device is delivered via a minimally invasive right-sided femoral catheterization procedure and has FDA Breakthrough Device Designation and CE Mark approval.

Is V-Wave a public or private company?

V-Wave is a private company. It is classified as corporate owned and is currently acquired.

When was V-Wave founded?

V-Wave was founded in 2009. It employs 11 to 50 people.

Where is V-Wave based?

V-Wave is headquartered in Caesarea, Israel, in the Middle East region.

How does V-Wave make money?

One revenue line is on record: medical Device Sales (Planned).

Who are V-Wave's main competitors?

Corvia Medical is listed as a direct peer. Broad incumbents are Edwards Lifesciences, Abbott, Medtronic and Boston Scientific. Emerging players are Ancora Heart, BioVentrix, Cardiac Dimensions and Axon Therapies. Shockwave Medical is listed as an others.

Does V-Wave have an API?

No public API is recorded for V-Wave.

What industry is V-Wave in?

V-Wave's product category is Cardiovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation), with a secondary code of HLAKABAB, Interventional Cardiology (PCI/Structural Heart). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comStructure of the Congestive Heart Failure (CHF) Market, Emerging Trends, and Key Player AnalysisThe Business Research Company published a market analysis projecting the global congestive heart failure (CHF) market to reach $23.79 billion by 2030, growing at a compound annual growth rate of 6.8%. Key drivers cited include rising heart failure prevalence, improved diagnostic technologies, increased homecare adoption, and efforts to reduce hospital readmissions. Notable developments include Johnson & Johnson's acquisition of Israel-based V-Wave Ltd. in October 2024 to expand its cardiovascular MedTech portfolio, and AMBU A/S's January 2025 launch of a new video laryngoscopy system for airway management.openPR.comCompetitive Landscape: Key Market Leaders and Emerging Competitors in the Cardiac Prosthetic Devices IndustryThe cardiac prosthetic devices market is projected to reach $15.57 billion by 2030, growing at a compound annual growth rate of 11.3%, driven by an aging global population, rising demand for minimally invasive cardiac therapies, and increasing heart failure incidence. In October 2024, Johnson & Johnson acquired Israel-based V-Wave Ltd. for an undisclosed price to expand its portfolio in cardiac prosthetics and structural heart devices using V-Wave's Ventura interatrial shunt. In April 2024, Abbott launched its TriClip G4 System, a transcatheter edge-to-edge repair device designed to treat severe tricuspid regurgitation via femoral vein catheter insertion.tctmd.comHolding Out Hope for HF Shunts, Even After an FDA Panel’s DoubtsAn FDA advisory panel declined to endorse V-Wave's Ventura interatrial shunt for heart failure patients because the primary trial endpoint was missed, despite showing benefits in a specific subgroup. Experts maintain that the technology holds potential but emphasize that rigorous patient selection and further confirmatory studies are necessary to validate efficacy and safety. The decision highlights the complexity of treating heart failure phenotypes and the high evidentiary standards required for regulatory approval.MedicaldesignandoutsourcingThis world-renowned cardiologist says the heart failure device era is approaching fastDr. William Abraham, Chief Medical Officer at V-Wave, predicts a significant expansion in the use of devices to treat heart failure with reduced ejection fraction (HFrEF) due to unmet medical needs. He highlights the potential of technologies like the Carillon device and emerging AI-driven closed-loop systems to improve patient outcomes and reduce hospitalizations. The interview also identifies acute decompensated heart failure and cardiorenal syndrome as key areas for future device innovation.BenzingaJohnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of EarningsJohnson & Johnson is set to release its third-quarter 2024 earnings results on October 15, with analysts projecting quarterly earnings of $2.21 per share, down from $2.66 per share in the year-ago period, while revenue is expected to reach $22.16 billion compared to $21.03 billion a year earlier. The company announced on October 9 that it had completed its acquisition of V-Wave, a medical device company focused on heart failure treatments. Analyst ratings from major firms show mixed sentiment, with Cantor Fitzgerald maintaining an Overweight rating while TD Cowen cut its price target and B of A Securities downgraded its outlook.NoCamelsJohnson & Johnson Completes Purchase Of Israeli Startup V-WaveJohnson & Johnson has completed its acquisition of Israeli medtech company V-Wave, which develops the Ventura Interatrial Shunt device for treating heart failure. The deal, announced in August, is valued at up to $1.7 billion, including a $600 million upfront payment and up to $1.1 billion in regulatory and commercial milestone payments. V-Wave has received FDA Breakthrough Device Designation and CE mark approval, and the technology has the potential to be the first device of its kind to reach the market.MassDeviceJohnson & Johnson completes $1.7B V-Wave acquisitionJohnson & Johnson has completed the acquisition of V-Wave, a New Jersey-based developer of cardiovascular implant technology, for up to $1.7 billion. This transaction adds V-Wave's Ventura interatrial shunt to J&J MedTech's portfolio, aiming to address unmet needs in heart failure treatment and expand J&J's presence in high-growth cardiovascular markets. The deal is expected to result in an approximately $600 million in-process R&D charge for J&J in the fourth quarter of 2024.BenzingaJohnson & Johnson's Golden Cross: A Bullish Prescription For Investors? - Johnson & Johnson (NYSE:JNJ)Johnson & Johnson's stock has achieved a Golden Cross technical pattern, with the 50-day simple moving average crossing above the 200-day moving average, signaling potential upward momentum as the stock trades at $164.43. The company has also submitted a Biologics License Application to the FDA for nipocalimab, a drug targeting generalized myasthenia gravis, alongside strategic acquisitions like V-Wave Ltd. to expand its oncology pipeline and bolster growth prospects.PitchBookGlobal exit & IPO news for August 21, 2024V-Wave, a developer of implantable devices for heart failure, has agreed to be acquired by Johnson & Johnson for up to $1.7 billion. Additionally, Corezi, a provider of cloud solutions for financial businesses, has also been acquired. The article highlights significant acquisition activity in the healthcare and technology sectors.Pulse 2.0Johnson & Johnson To Buy V-Wave For Up To $1.7 BillionJohnson & Johnson agreed to acquire V-Wave, a heart failure device developer, for $600 million upfront plus up to $1.1 billion in milestones. The deal, expected to close before end of 2024, adds V-Wave's Ventura Interatrial Shunt to J&J MedTech's cardiovascular portfolio.